Artikel
Bortezomib - a new approach in head & neck cancer therapy
Suche in Medline nach
Autoren
Veröffentlicht: | 8. August 2007 |
---|
Gliederung
Text
Proteasome inhibition has been shown to be an effective anticancer agent in the treatment of multiple myeloma disease as well as in solid tumors.
We investigated the antitumoral effects of Bortezomib in SCCHN cell lines and furthermore sought to identify drug interactions between Bortezomib, Docetaxel and Cisplatin (CDDP).
Eight different SCCHN cell lines were treated with descending doses of Docetaxel, CDDP or Bortezomib alone and with Docetaxel or CDDP each in combination with Bortezomib .
Apoptosis and cell viability were detected by cytohistology to quantitate drug effects.
Bortezomib as single used drug shows a remarkable anticancer effect in SCCHN cell lines but also in combination with Docetaxel or CDDP by inducing apoptosis and thus cell death.
Our results further suppose adding Bortezomib to Docetaxel-or CDDP -Regime may improve Docetaxel-/CDDP treatment intensifying antiproliferative effects.
Bortezomib and Docetaxel-/CDDP-Regime represent an additive drug combination that warrants further evaluation in in- vivo models of head and neck cancer.